That's interesting TripAces.
Is my memory correct? I recall something along the lines that the Neurology division of the FDA was very supportive of Trofinetide's phase 2 trials in Rhett, but the Psychiatry division was nowhere as supportive of the phase 2 in Fragile X? Or was it that Neurology was supportive of proceeding to phase 3 for Rhett but Psychiatry wasn't so supportive of advancing to Phase 3 for Fragile X, despite promising phase 2 results?
Anyway, if what you say is true, I'm delighted that Phelan-McDermid and Pitt Hopkins fall under Neurology.
- Forums
- ASX - By Stock
- Ann: US patent to 2034 granted for Neuren's NNZ-2591 in autism
That's interesting TripAces. Is my memory correct? I recall...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.61 |
Change
0.400(2.63%) |
Mkt cap ! $1.996B |
Open | High | Low | Value | Volume |
$15.51 | $15.82 | $15.46 | $2.639M | 169.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 2099 | $15.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.62 | 404 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 315 | 15.610 |
19 | 2123 | 15.600 |
4 | 378 | 15.590 |
6 | 543 | 15.580 |
6 | 689 | 15.570 |
Price($) | Vol. | No. |
---|---|---|
15.620 | 182 | 8 |
15.630 | 726 | 13 |
15.640 | 759 | 13 |
15.650 | 400 | 3 |
15.660 | 429 | 4 |
Last trade - 13.01pm 30/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
SPONSORED BY The Market Online